Clinical Trials Arena June 6, 2024
lawrence

Welcome to the third of five episodes in our podcast series “Digital Deals in Life Sciences – What Makes Them Different?” Transactions involving digital assets are becoming an increasing focus for pharmaceutical companies. In this series, life sciences industry M&A veteran and Sterling Technology board advisor John Easton discusses how these differ from traditional life science deals, and what both parties should look out for to increase the chances of deal success, mitigate risks, and avoid failure.

...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Conferences / Podcast, Digital Health, Mergers & Acquisitions / JV, Pharma / Biotech, Technology, Trends
Navigating Complex Regulatory Landscapes in the Biopharmaceutical Industry
How Life Sciences Can Drive Innovation And Sustainability In Returns Management
10X Genomics at JPM: New Products, New Sales Team, New Markets
Enhancing Target Screening with CRISPR Libraries: Revolutionizing Drug Discovery and Functional Genomics
Daiichi Sankyo Announces New CEO

Share This Article